Boehringer Ingelheim has announced an €85 million expansion to the BI microParts GmbH inhaler manufacturing facililty in Dortmund, Germany meant to double its annual production of Respimat inhalers to 44 million by 2015. Filling of the Respimat inhalers takes place in Ingelheim.
The company says that it will need to add more than 100 new hires to the existing 450 employees at the site in order to handle the increased capacity.
Board member Wolfram Carius commented, “We expect that the Respimat business will continue its strong growth. For this reason, Boehringer Ingelheim is now laying the symbolic foundation stone to expand production capacity for the Respimat Soft Inhaler at the Dortmund facility. In future, we will continue to meet the increasing demand, while at the same time fulfilling our claim to provide patients with innovative medications.”
Read the Boehringer Ingelheim press release.
